Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis

Purpose of review Bronchiectasis from cystic fibrosis and noncystic fibrosis causes include a spectrum of chronic suppurative airway conditions that share key pathophysiologic mechanisms but differ substantially in genetic basis, epidemiology, and clinical course. Recent therapeutic advances, particularly highly effective CFTR modulators in cystic fibrosis and emerging anti-inflammatory therapies in bronchiectasis, have reshaped disease management and prompted re-evaluation of treatment paradigms, outcome measures, and approaches to long-term monitoring. Recent findings In cystic fibrosis, highly effective CFTR modulator therapy, including elexacaftor/tezacaftor/ivacaftor and the recently approved once daily vanzacaftor/tezacaftor/deutivacaftor, has produced sustained increase in lung function, reduced frequency of pulmonary exacerbations, and improved quality of life, while highlighting the limitations of FEV 1 as a sole future marker of treatment response. In noncystic fibrosis bronchiectasis, the phase 3 ASPEN trial demonstrated that brensocatib, a dipeptidyl peptidase-1 inhibitor, significantly reduces exacerbation frequency and slows lung function decline at the higher dose, representing a potential disease-modifying therapy. Emerging evidence also underscores the prognostic importance of comorbidities and disease modifiers, including Pseudomonas aeruginosa and gastroesophageal reflux disease. Summary Management of all forms of bronchiectasis is increasingly shifting toward individualized, endotype-directed care. Integration of disease-modifying therapies, systematic assessment of comorbidities, validated severity stratification tools, and patient-reported outcomes will be essential to optimizing long-term clinical outcomes and advancing precision medicine approaches across this heterogeneous disease spectrum.